

**ANZ
DATA**



AUSTRALIA &
NEW ZEALAND
DIALYSIS & TRANSPLANT
REGISTRY

MISSING DATA REPORT

Survey Data 2019 – 2023

[Abstract](#)

The rates of non-response for ANZDATA
survey items over the last 5 years

www.anzdata.org.au
anzdata@anzdata.org.au

ANZDATA Missing Data Report



The tables below show the rates of non-response for ANZDATA survey items over the last 5 years, as N (%). The first row (Frequency) shows the number of patients that should have a response for the item. As rates of non-response have increased in recent years, individual hospital missing data reports will also be produced and supplied to units to highlight areas where reporting should improve. Rates can appear higher in the latest survey year as not all survey queries are received by the date of data lock.

Table 1 Demographics

Variable	2019	2020	2021	2022	2023
Frequency	3970	4053	4082	4145	4161
Date of birth	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Gender	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Country of birth	32 (0.8%)	12 (0.3%)	41 (1.0%)	13 (0.3%)	24 (0.6%)
Late referral seen <3 mths before 1st treatment	57 (1.4%)	38 (0.9%)	61 (1.5%)	43 (1.0%)	104 (2.5%)
Ethnicity 1	83 (2.1%)	78 (1.9%)	57 (1.4%)	71 (1.7%)	105 (2.5%)
Primary kidney disease major heading	27 (0.7%)	27 (0.7%)	22 (0.5%)	42 (1.0%)	75 (1.8%)
Was native kidney biopsied?	116 (2.9%)	49 (1.2%)	68 (1.7%)	41 (1.0%)	101 (2.4%)
Genetic test performed?	3173 (79.9%)	3072 (75.8%)	2983 (73.1%)	2874 (69.3%)	688 (16.5%)
Serum creatinine at entry	74 (1.9%)	66 (1.6%)	49 (1.2%)	39 (0.9%)	59 (1.4%)
Height at KRT entry (cm)	147 (3.7%)	74 (1.8%)	70 (1.7%)	64 (1.5%)	94 (2.3%)
Weight at KRT entry (kg)	75 (1.9%)	28 (0.7%)	56 (1.4%)	31 (0.7%)	43 (1.0%)
Smoking status at KRT entry	96 (2.4%)	53 (1.3%)	84 (2.1%)	61 (1.5%)	74 (1.8%)

Table 2 Comorbidities at KRT entry

Variable	2019	2020	2021	2022	2023
Frequency	3970	4053	4082	4145	4161
Postcode	58 (1.5%)	28 (0.7%)	46 (1.1%)	36 (0.9%)	38 (0.9%)
Chronic lung disease	67 (1.7%)	28 (0.7%)	18 (0.4%)	31 (0.7%)	80 (1.9%)
Coronary artery disease	68 (1.7%)	29 (0.7%)	19 (0.5%)	32 (0.8%)	82 (2.0%)
Peripheral vascular disease	66 (1.7%)	27 (0.7%)	17 (0.4%)	33 (0.8%)	82 (2.0%)
Cerebrovascular disease	67 (1.7%)	28 (0.7%)	19 (0.5%)	34 (0.8%)	79 (1.9%)
Diabetes	42 (1.1%)	27 (0.7%)	42 (1.0%)	37 (0.9%)	78 (1.9%)
Cancer ever diagnosed?	85 (2.1%)	19 (0.5%)	111 (2.7%)	42 (1.0%)	91 (2.2%)
Hepatitis C Antibody	122 (3.1%)	45 (1.1%)	24 (0.6%)	37 (0.9%)	96 (2.3%)
Calciophylaxis Episode	602 (15.2%)	28 (0.7%)	60 (1.5%)	23 (0.6%)	97 (2.3%)
Non-Registry Trials	764 (19.2%)	147 (3.6%)	859 (21.0%)	167 (4.0%)	925 (22.2%)

ANZDATA Missing Data Report



Table 3 Comorbidities at survey date

Variable	2019	2020	2021	2022	2023
Frequency	35636	36851	38086	39235	39659
Postcode	418 (1.2%)	142 (0.4%)	431 (1.1%)	417 (1.1%)	390 (1.0%)
Chronic lung disease	164 (0.5%)	157 (0.4%)	156 (0.4%)	140 (0.4%)	189 (0.5%)
Coronary artery disease	165 (0.5%)	157 (0.4%)	157 (0.4%)	141 (0.4%)	190 (0.5%)
Peripheral vascular disease	163 (0.5%)	156 (0.4%)	154 (0.4%)	145 (0.4%)	191 (0.5%)
Cerebrovascular disease	167 (0.5%)	160 (0.4%)	160 (0.4%)	145 (0.4%)	190 (0.5%)
Diabetes	146 (0.4%)	147 (0.4%)	173 (0.5%)	141 (0.4%)	182 (0.5%)
Cancer ever diagnosed?	137 (0.4%)	115 (0.3%)	212 (0.6%)	119 (0.3%)	160 (0.4%)
Hepatitis C Antibody	233 (0.7%)	199 (0.5%)	137 (0.4%)	143 (0.4%)	211 (0.5%)
Calciphylaxis Episode	1537 (4.3%)	861 (2.3%)	889 (2.3%)	76 (0.2%)	127 (0.3%)
Non-Registry Trials	3709 (10.4%)	1158 (3.1%)	3048 (8.0%)	405 (1.0%)	2574 (6.5%)

Table 4 Reason for change from CAPD to APD

Variable	2019	2020	2021	2022	2023
Frequency	655	633	644	669	567
Reason transfer from dialysis during survey	71 (10.8%)	54 (8.5%)	132 (20.5%)	72 (10.8%)	12 (2.1%)

Table 5 Reason for change from APD to CAPD

Variable	2019	2020	2021	2022	2023
Frequency	110	112	169	103	106
Reason transfer from dialysis during survey	15 (13.6%)	16 (14.3%)	65 (38.5%)	11 (10.7%)	0 (0.0%)

Table 6 Reason for change from PD to HD

Variable	2019	2020	2021	2022	2023
Frequency	802	839	919	844	854
Reason transfer from dialysis during survey	69 (8.6%)	52 (6.2%)	82 (8.9%)	51 (6.0%)	14 (1.6%)

Table 7 Reason for change from HD to PD

Variable	2019	2020	2021	2022	2023
Frequency	530	522	508	476	518
Reason transfer from dialysis during survey	23 (4.3%)	31 (5.9%)	56 (11.0%)	23 (4.8%)	5 (1.0%)

Table 8 Reason for change from PD to Hybrid

Variable	2019	2020	2021	2022	2023
Frequency	0	0	0	0	25
Reason transfer from dialysis during survey	-	-	-	-	1 (4.0%)

ANZDATA Missing Data Report



Table 9 Cause of death

Variable	2019	2020	2021	2022	2023
Frequency	2842	2848	2996	3737	3358
Cause of death	119 (4.2%)	117 (4.1%)	114 (3.8%)	218 (5.8%)	127 (3.8%)

Table 10 Dialysis data

Variable	2019	2020	2021	2022	2023
Frequency	20547	21104	21888	22705	22930
Dialysis type	970 (4.7%)	1034 (4.9%)	1165 (5.3%)	786 (3.5%)	838 (3.7%)
Self-care dialysis (performed by the patient with minimal assistance)	-	1244 (5.9%)	1217 (5.6%)	834 (3.7%)	851 (3.7%)
Dry Weight on last dialysis: End Survey, Transplantation or Death	1016 (4.9%)	1160 (5.5%)	1486 (6.8%)	949 (4.2%)	973 (4.2%)
Uncorrected calcium levels (mmol/l)	1143 (5.6%)	1437 (6.8%)	1350 (6.2%)	1346 (5.9%)	1088 (4.7%)
Phosphate levels (mmol/l)	1145 (5.6%)	1411 (6.7%)	1365 (6.2%)	1347 (5.9%)	1091 (4.8%)
Haemoglobin level nearest end Survey (g/l)	1135 (5.5%)	1397 (6.6%)	1334 (6.1%)	1332 (5.9%)	1064 (4.6%)
EPO Agent	1066 (5.2%)	1243 (5.9%)	1677 (7.7%)	1364 (6.0%)	996 (4.3%)
Ferritin within last 3 months of Survey	2051 (10.0%)	2588 (12.3%)	2543 (11.6%)	2695 (11.9%)	2246 (9.8%)
% Saturation Iron (Transferrin Saturation) within last 3 months of survey	2746 (13.4%)	2945 (14.0%)	2780 (12.7%)	2987 (13.2%)	2523 (11.0%)

Table 11 Haemodialysis data

Variable	2019	2020	2021	2022	2023
Frequency	16920	17403	18110	18855	19146
Dialyser brand, model, membrane, surface area	1027 (6.1%)	886 (5.1%)	984 (5.4%)	799 (4.2%)	824 (4.3%)
Blood flow rate (mls/min)	1026 (6.1%)	897 (5.2%)	998 (5.5%)	814 (4.3%)	809 (4.2%)
Frequency of dialysis per week	999 (5.9%)	869 (5.0%)	979 (5.4%)	798 (4.2%)	785 (4.1%)
Hours per session	1016 (6.0%)	884 (5.1%)	1015 (5.6%)	790 (4.2%)	790 (4.1%)
Adequacy method (urea reduction or Kt/V)	3643 (21.5%)	3172 (18.2%)	3537 (19.5%)	3540 (18.8%)	3055 (16.0%)
Adequacy value (Urea reduction ratio % or Kt/V value on HD)	3643 (21.5%)	3172 (18.2%)	3537 (19.5%)	3540 (18.8%)	3082 (16.1%)
Vascular access in use at last haemodialysis	1066 (6.3%)	920 (5.3%)	1061 (5.9%)	808 (4.3%)	837 (4.4%)

Table 12 HDF volume

Variable	2019	2020	2021	2022	2023
Frequency	5099	5240	4979	5199	5317
HDF volume (L) (If on HDF)	789 (15.5%)	653 (12.5%)	472 (9.5%)	729 (14.0%)	509 (9.6%)

Table 13 Access at first HD

Variable	2019	2020	2021	2022	2023
Frequency	3352	3305	3447	3560	3565
Vascular access in use at first haemodialysis	156 (4.7%)	124 (3.8%)	102 (3.0%)	94 (2.6%)	57 (1.6%)

ANZDATA Missing Data Report



Table 14 Peritoneal dialysis data

Variable	2019	2020	2021	2022	2023
Frequency	4733	4863	4953	4972	4946
Type of Peritoneal Connection System	261 (5.5%)	306 (6.3%)	355 (7.2%)	185 (3.7%)	169 (3.4%)
Total volume weekly exchanges - All PD	333 (7.0%)	333 (6.8%)	635 (12.8%)	238 (4.8%)	209 (4.2%)
PD Solution Glucose	274 (5.8%)	321 (6.6%)	409 (8.3%)	207 (4.2%)	178 (3.6%)
PD Solution Icodextrin	288 (6.1%)	322 (6.6%)	410 (8.3%)	209 (4.2%)	177 (3.6%)
PD Solution Low GDP (either Lactate or Bicarbonate)	276 (5.8%)	327 (6.7%)	413 (8.3%)	213 (4.3%)	181 (3.7%)
Creatinine Clearance (litres/week/1.73m ²)	1652 (34.9%)	1979 (40.7%)	2165 (43.7%)	2007 (40.4%)	2169 (43.9%)
Dialysate Only Weekly Kt/V value on PD	1644 (34.7%)	1976 (40.6%)	2146 (43.3%)	1997 (40.2%)	2171 (43.9%)
Residual kidney function (creatinine clearance - litres/week/1.73m ²)	1667 (35.2%)	1986 (40.8%)	2181 (44.0%)	2024 (40.7%)	2184 (44.2%)
Number of episodes peritonitis during survey	777 (16.4%)	945 (19.4%)	1199 (24.2%)	1060 (21.3%)	1435 (29.0%)
Residual Urine Volume (mL/24 hrs)	2709 (57.2%)	2860 (58.8%)	2645 (53.4%)	2448 (49.2%)	2482 (50.2%)

Table 15 Peritoneal dialysis PET test

Variable	2019	2020	2021	2022	2023
Frequency	1368	1542	1481	1390	1444
PET test for PD-within first 6 mths starting?	979 (71.6%)	1009 (65.4%)	995 (67.2%)	926 (66.6%)	840 (58.2%)

Table 16 Peritoneal dialysis catheter date

Variable	2019	2020	2021	2022	2023
Frequency	0	0	0	0	1444
First peritoneal catheter insertion date	-	-	-	-	45 (3.1%)

Table 17 Peritonitis episodes data

Variable	2019	2020	2021	2022	2023
Frequency	922	986	1049	1210	1205
Was this a relapse or recurrence of peritonitis?	50 (5.4%)	8 (0.8%)	8 (0.8%)	7 (0.6%)	1 (0.1%)
Technique at time of infection	2 (0.2%)	3 (0.3%)	2 (0.2%)	1 (0.1%)	2 (0.2%)
Antifungal Therapy?	112 (12.1%)	48 (4.9%)	33 (3.1%)	14 (1.2%)	8 (0.7%)
Name of initial regimen first antibiotic given	51 (5.5%)	21 (2.1%)	8 (0.8%)	3 (0.2%)	1 (0.1%)
Name of final regimen first antibiotic given	90 (9.8%)	49 (5.0%)	20 (1.9%)	28 (2.3%)	50 (4.1%)
Glucose PD Solution at time of infection?	82 (8.9%)	53 (5.4%)	53 (5.1%)	35 (2.9%)	22 (1.8%)
Icodextrin PD Solution at time of infection?	83 (9.0%)	58 (5.9%)	53 (5.1%)	36 (3.0%)	22 (1.8%)
Low GDP PD Solution (either Lactate or Bicarbonate) at time of infection?	85 (9.2%)	62 (6.3%)	55 (5.2%)	40 (3.3%)	23 (1.9%)
Was patient hospitalised overnight?	62 (6.7%)	41 (4.2%)	5 (0.5%)	6 (0.5%)	4 (0.3%)
Was catheter removed?	50 (5.4%)	36 (3.7%)	9 (0.9%)	7 (0.6%)	14 (1.2%)
Did patient have interim haemodialysis?	69 (7.5%)	38 (3.9%)	11 (1.0%)	16 (1.3%)	10 (0.8%)
Did patient transfer to permanent haemodialysis?	53 (5.7%)	40 (4.1%)	11 (1.0%)	10 (0.8%)	15 (1.2%)

ANZDATA Missing Data Report



Table 18 Transplant baseline data

Variable	2019	2020	2021	2022	2023
Frequency	1315	1072	1044	1112	1263
Recipient CMV antibody status	25 (1.9%)	54 (5.0%)	25 (2.4%)	5 (0.4%)	43 (3.4%)
Recipient EBV antibody status	27 (2.1%)	55 (5.1%)	25 (2.4%)	4 (0.4%)	42 (3.3%)
Donor source	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor age	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Donor sex	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Total ischaemia (to nearest hour)	82 (6.2%)	35 (3.3%)	22 (2.1%)	21 (1.9%)	57 (4.5%)
Immediate function	26 (2.0%)	18 (1.7%)	12 (1.1%)	10 (0.9%)	54 (4.3%)
HLA-A mismatch	5 (0.4%)	9 (0.8%)	0 (0.0%)	2 (0.2%)	8 (0.6%)
HLA-B mismatch	5 (0.4%)	9 (0.8%)	0 (0.0%)	2 (0.2%)	8 (0.6%)
HLA-DR mismatch	5 (0.4%)	9 (0.8%)	0 (0.0%)	2 (0.2%)	8 (0.6%)
HLA-DQ mismatch	188 (14.3%)	86 (8.0%)	12 (1.1%)	2 (0.2%)	8 (0.6%)
Donor blood group	0 (0.0%)	4 (0.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Recipient blood group	0 (0.0%)	3 (0.3%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Recipient authorised match PRA from OrganMatch	6 (0.5%)	9 (0.8%)	0 (0.0%)	2 (0.2%)	8 (0.6%)

Table 19 Transplant Surgical data - of all transplants

Variable	2019	2020	2021	2022	2023
Frequency	1315	1072	1044	1112	1263
At least one anastomosis in transplant surgical data	803 (61.1%)	245 (22.9%)	98 (9.4%)	40 (3.6%)	91 (7.2%)

Table 20 Transplant Surgical data - of all anastomoses

Variable	2019	2020	2021	2022	2023
Frequency	537	872	977	1092	1183
Anastomosis site	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Arterial	27 (5.0%)	26 (3.0%)	28 (2.9%)	2 (0.2%)	7 (0.6%)
Venous	27 (5.0%)	29 (3.3%)	28 (2.9%)	3 (0.3%)	6 (0.5%)
Vena cava extension	32 (6.0%)	28 (3.2%)	8 (0.8%)	3 (0.3%)	13 (1.1%)
Aortic patch	31 (5.8%)	25 (2.9%)	6 (0.6%)	2 (0.2%)	10 (0.8%)
Anastomosis time (min)	63 (11.7%)	51 (5.8%)	30 (3.1%)	26 (2.4%)	22 (1.9%)

Table 21 Graft failure data

Variable	2019	2020	2021	2022	2023
Frequency	323	324	343	380	344
Cause of graft failure	56 (17.3%)	20 (6.2%)	12 (3.5%)	18 (4.7%)	18 (5.2%)
Serum creatinine at graft failure	70 (21.7%)	36 (11.1%)	26 (7.6%)	48 (12.6%)	34 (9.9%)

ANZDATA Missing Data Report



Table 22 Rejection data

Variable	2019	2020	2021	2022	2023
Frequency	408	415	362	313	480
Was a biopsy performed?	2 (0.5%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Response of this rejection to treatment	26 (6.4%)	44 (10.6%)	40 (11.0%)	24 (7.7%)	23 (4.8%)
Primary treatment of rejection	2 (0.5%)	20 (4.8%)	10 (2.8%)	3 (1.0%)	14 (2.9%)

Table 23 Rejection data if biopsy performed

Variable	2019	2020	2021	2022	2023
Frequency	401	410	349	305	468
If biopsy is Yes ?Cellular	4 (1.0%)	336 (82.0%)	-	-	-
If biopsy is Yes ?Glomerular	14 (3.5%)	335 (81.7%)	-	-	-
If biopsy is Yes ?Vascular	13 (3.2%)	335 (81.7%)	-	-	-
Humoral Rejection	29 (7.2%)	335 (81.7%)	-	-	-
If biopsy is Yes ?Antibody mediated	-	162 (39.5%)	6 (1.7%)	3 (1.0%)	9 (1.9%)
If biopsy is Yes ?T-cell mediated	-	154 (37.6%)	7 (2.0%)	4 (1.3%)	8 (1.7%)
If biopsy is Yes ?Presence of donor specific antibody(DSA)	-	337 (82.2%)	232 (66.5%)	198 (64.9%)	281 (60.0%)
If biopsy is Yes and Banff g is known	22 (5.5%)	44 (10.7%)	34 (9.7%)	37 (12.1%)	69 (14.7%)
If biopsy is Yes and Banff i is known	19 (4.7%)	41 (10.0%)	37 (10.6%)	30 (9.8%)	62 (13.2%)
If biopsy is Yes and Banff t is known	20 (5.0%)	37 (9.0%)	33 (9.5%)	30 (9.8%)	46 (9.8%)
If biopsy is Yes and Banff v is known	21 (5.2%)	48 (11.7%)	57 (16.3%)	50 (16.4%)	84 (17.9%)
If biopsy is Yes and Banff ptc is known	52 (13.0%)	51 (12.4%)	48 (13.8%)	52 (17.0%)	74 (15.8%)
If biopsy is Yes and Banff c4d is known	-	202 (49.3%)	84 (24.1%)	76 (24.9%)	114 (24.4%)
If biopsy is Yes and Banff cg is known	-	208 (50.7%)	73 (20.9%)	58 (19.0%)	113 (24.1%)
If biopsy is Yes and Banff ci is known	-	220 (53.7%)	69 (19.8%)	59 (19.3%)	84 (17.9%)
If biopsy is Yes and Banff ct is known	-	219 (53.4%)	69 (19.8%)	58 (19.0%)	88 (18.8%)
If biopsy is Yes and Banff cv is known	-	220 (53.7%)	80 (22.9%)	69 (22.6%)	116 (24.8%)
If biopsy is Yes and Banff mm is known	-	239 (58.3%)	132 (37.8%)	93 (30.5%)	140 (29.9%)
If biopsy is Yes and Banff ah is known	-	205 (50.0%)	80 (22.9%)	83 (27.2%)	119 (25.4%)
If biopsy is Yes and Banff ti is known	-	237 (57.8%)	116 (33.2%)	88 (28.9%)	127 (27.1%)
If biopsy is Yes and Banff i-IFTA is known	-	253 (61.7%)	140 (40.1%)	103 (33.8%)	171 (36.5%)

Table 24 Rejection data if biopsy not performed

Variable	2019	2020	2021	2022	2023
Frequency	5	5	13	8	12
Likelihood of rejection if biopsy not performed	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

ANZDATA Missing Data Report



Table 25 Rejection data - AMR

Variable	2019	2020	2021	2022	2023
Frequency	0	5	85	94	131
History of Non-Adherence?	-	-	61 (71.8%)	75 (79.8%)	103 (78.6%)
CNI Type	-	-	61 (71.8%)	78 (83.0%)	109 (83.2%)
CNI Level type code	-	-	61 (71.8%)	79 (84.0%)	109 (83.2%)
CNI Level	-	-	64 (75.3%)	83 (88.3%)	114 (87.0%)
MMF dose (mg)(daily)	-	-	64 (75.3%)	82 (87.2%)	111 (84.7%)
MPA dose (mg)(daily)	-	-	77 (90.6%)	90 (95.7%)	127 (96.9%)
Prednisolone dose (mg)(daily)	-	-	61 (71.8%)	80 (85.1%)	110 (84.0%)
Creatinine umol/L	-	-	61 (71.8%)	80 (85.1%)	111 (84.7%)
Urine Protein / Creatinine Ratio	-	-	74 (87.1%)	85 (90.4%)	120 (91.6%)
Albumin / Creatinine Ratio	-	-	78 (91.8%)	91 (96.8%)	122 (93.1%)
New-onset CMV Viraemia in the preceding 12 months?	-	-	63 (74.1%)	80 (85.1%)	109 (83.2%)
New-onset BK Viraemia in the preceding 12 months?	-	-	63 (74.1%)	80 (85.1%)	109 (83.2%)
Parenthood in last 12 months?	-	-	63 (74.1%)	80 (85.1%)	105 (80.2%)

Table 26 Transplant follow-up data, 0 months

Variable	2019	2020	2021	2022	2023
Frequency	1340	1078	1055	1129	1281
Weight	75 (5.6%)	58 (5.4%)	30 (2.8%)	82 (7.3%)	55 (4.3%)
Drug data	44 (3.3%)	24 (2.2%)	32 (3.0%)	84 (7.4%)	59 (4.6%)

Table 27 Transplant follow-up data, 1 months

Variable	2019	2020	2021	2022	2023
Frequency	1328	1056	1025	1107	1256
Weight	38 (2.9%)	49 (4.6%)	64 (6.2%)	65 (5.9%)	63 (5.0%)
Serum creatinine	31 (2.3%)	29 (2.7%)	58 (5.7%)	56 (5.1%)	54 (4.3%)
Drug data	30 (2.3%)	30 (2.8%)	70 (6.8%)	95 (8.6%)	62 (4.9%)

Table 28 Transplant follow-up data, 2 months

Variable	2019	2020	2021	2022	2023
Frequency	1325	1053	1051	1061	1236
Weight	62 (4.7%)	78 (7.4%)	107 (10.2%)	111 (10.5%)	129 (10.4%)
Serum creatinine	49 (3.7%)	49 (4.7%)	82 (7.8%)	91 (8.6%)	104 (8.4%)
Drug data	55 (4.2%)	54 (5.1%)	100 (9.5%)	117 (11.0%)	106 (8.6%)

ANZDATA Missing Data Report



Table 29 Transplant follow-up data, 3 months

Variable	2019	2020	2021	2022	2023
Frequency	1294	1088	1050	1066	1218
Weight	89 (6.9%)	88 (8.1%)	123 (11.7%)	125 (11.7%)	141 (11.6%)
Serum creatinine	70 (5.4%)	63 (5.8%)	101 (9.6%)	100 (9.4%)	108 (8.9%)
Drug data	73 (5.6%)	69 (6.3%)	107 (10.2%)	127 (11.9%)	105 (8.6%)

Table 30 Transplant follow-up data, 6 months

Variable	2019	2020	2021	2022	2023
Frequency	1302	1071	1112	1031	1180
Weight	158 (12.1%)	154 (14.4%)	179 (16.1%)	155 (15.0%)	214 (18.1%)
Serum creatinine	113 (8.7%)	110 (10.3%)	127 (11.4%)	115 (11.2%)	160 (13.6%)
Drug data	122 (9.4%)	115 (10.7%)	141 (12.7%)	138 (13.4%)	171 (14.5%)

Table 31 Transplant follow-up data, 12 months

Variable	2019	2020	2021	2022	2023
Frequency	1290	1280	1029	1002	1078
Weight	161 (12.5%)	195 (15.2%)	160 (15.5%)	185 (18.5%)	183 (17.0%)
Serum creatinine	105 (8.1%)	148 (11.6%)	109 (10.6%)	129 (12.9%)	141 (13.1%)
Drug data	101 (7.8%)	137 (10.7%)	119 (11.6%)	149 (14.9%)	139 (12.9%)

Table 32 Transplant follow-up data, 24 months

Variable	2019	2020	2021	2022	2023
Frequency	1230	1266	1250	994	969
Weight	165 (13.4%)	212 (16.7%)	187 (15.0%)	180 (18.1%)	187 (19.3%)
Serum creatinine	103 (8.4%)	133 (10.5%)	124 (9.9%)	123 (12.4%)	147 (15.2%)
Drug data	106 (8.6%)	139 (11.0%)	139 (11.1%)	144 (14.5%)	150 (15.5%)

Table 33 Transplant follow-up data, 36 months

Variable	2019	2020	2021	2022	2023
Frequency	1157	1198	1237	1201	958
Weight	167 (14.4%)	217 (18.1%)	207 (16.7%)	184 (15.3%)	176 (18.4%)
Serum creatinine	99 (8.6%)	150 (12.5%)	104 (8.4%)	120 (10.0%)	126 (13.2%)
Drug data	101 (8.7%)	152 (12.7%)	114 (9.2%)	136 (11.3%)	126 (13.2%)

Table 34 Transplant follow-up data, 60 months

Variable	2019	2020	2021	2022	2023
Frequency	893	916	1089	1098	1144
Weight	148 (16.6%)	174 (19.0%)	196 (18.0%)	186 (16.9%)	216 (18.9%)
Serum creatinine	95 (10.6%)	105 (11.5%)	116 (10.7%)	122 (11.1%)	146 (12.8%)
Drug data	102 (11.4%)	110 (12.0%)	125 (11.5%)	123 (11.2%)	156 (13.6%)

ANZDATA Missing Data Report



Table 35 Transplant follow-up data, 84 months

Variable	2019	2020	2021	2022	2023
Frequency	747	785	824	829	1008
Weight	127 (17.0%)	150 (19.1%)	156 (18.9%)	128 (15.4%)	204 (20.2%)
Serum creatinine	63 (8.4%)	97 (12.4%)	94 (11.4%)	76 (9.2%)	149 (14.8%)
Drug data	76 (10.2%)	97 (12.4%)	102 (12.4%)	79 (9.5%)	158 (15.7%)

Table 36 Transplant follow-up data, 120 months

Variable	2019	2020	2021	2022	2023
Frequency	633	647	626	633	668
Weight	95 (15.0%)	128 (19.8%)	118 (18.8%)	119 (18.8%)	140 (21.0%)
Serum creatinine	56 (8.8%)	86 (13.3%)	73 (11.7%)	72 (11.4%)	96 (14.4%)
Drug data	69 (10.9%)	92 (14.2%)	78 (12.5%)	75 (11.8%)	99 (14.8%)

Table 37 Transplant follow-up data, 180 months

Variable	2019	2020	2021	2022	2023
Frequency	372	343	355	345	440
Weight	67 (18.0%)	60 (17.5%)	66 (18.6%)	60 (17.4%)	91 (20.7%)
Serum creatinine	40 (10.8%)	35 (10.2%)	34 (9.6%)	38 (11.0%)	69 (15.7%)
Drug data	45 (12.1%)	42 (12.2%)	40 (11.3%)	40 (11.6%)	71 (16.1%)

Table 38 Transplant follow-up data, 240 months

Variable	2019	2020	2021	2022	2023
Frequency	199	219	215	259	223
Weight	37 (18.6%)	49 (22.4%)	44 (20.5%)	50 (19.3%)	59 (26.5%)
Serum creatinine	22 (11.1%)	32 (14.6%)	32 (14.9%)	28 (10.8%)	44 (19.7%)
Drug data	25 (12.6%)	35 (16.0%)	32 (14.9%)	29 (11.2%)	46 (20.6%)

Table 39 Transplant follow-up data, 300 months

Variable	2019	2020	2021	2022	2023
Frequency	99	105	131	140	141
Weight	19 (19.2%)	23 (21.9%)	31 (23.7%)	31 (22.1%)	41 (29.1%)
Serum creatinine	10 (10.1%)	18 (17.1%)	14 (10.7%)	27 (19.3%)	27 (19.1%)
Drug data	12 (12.1%)	18 (17.1%)	15 (11.5%)	27 (19.3%)	28 (19.9%)

Table 40 Transplant follow-up data, 360 months

Variable	2019	2020	2021	2022	2023
Frequency	54	50	55	66	49
Weight	9 (16.7%)	10 (20.0%)	14 (25.5%)	14 (21.2%)	14 (28.6%)
Serum creatinine	4 (7.4%)	7 (14.0%)	7 (12.7%)	7 (10.6%)	11 (22.4%)
Drug data	6 (11.1%)	6 (12.0%)	7 (12.7%)	8 (12.1%)	10 (20.4%)

ANZDATA Missing Data Report



Table 41 Transplant follow-up data, 420 months

Variable	2019	2020	2021	2022	2023
Frequency	24	29	32	30	30
Weight	6 (25.0%)	8 (27.6%)	6 (18.8%)	5 (16.7%)	3 (10.0%)
Serum creatinine	4 (16.7%)	5 (17.2%)	1 (3.1%)	3 (10.0%)	1 (3.3%)
Drug data	6 (25.0%)	5 (17.2%)	2 (6.2%)	3 (10.0%)	1 (3.3%)

Table 42 Transplant follow-up data, 480 months

Variable	2019	2020	2021	2022	2023
Frequency	15	14	18	15	15
Weight	3 (20.0%)	4 (28.6%)	5 (27.8%)	3 (20.0%)	5 (33.3%)
Serum creatinine	2 (13.3%)	3 (21.4%)	2 (11.1%)	2 (13.3%)	3 (20.0%)
Drug data	2 (13.3%)	3 (21.4%)	2 (11.1%)	2 (13.3%)	3 (20.0%)

Table 43 Transplant follow-up data, 540 months

Variable	2019	2020	2021	2022	2023
Frequency	4	4	7	10	9
Weight	1 (25.0%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	5 (55.6%)
Serum creatinine	0 (0.0%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	2 (22.2%)
Drug data	1 (25.0%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	2 (22.2%)

Table 44 Transplant follow-up data, 600 months

Variable	2019	2020	2021	2022	2023
Frequency	0	0	0	0	0
Weight	-	-	-	-	-
Serum creatinine	-	-	-	-	-
Drug data	-	-	-	-	-

Table 45 Paediatric assessment at entry

Variable	2019	2020	2021	2022	2023
Frequency	34	31	33	45	30
Height	1 (2.9%)	1 (3.2%)	0 (0.0%)	1 (2.2%)	3 (10.0%)
Weight	1 (2.9%)	0 (0.0%)	0 (0.0%)	1 (2.2%)	3 (10.0%)
Paediatric Assessment at end of each Survey	2 (5.9%)	1 (3.2%)	2 (6.1%)	2 (4.4%)	3 (10.0%)

ANZDATA Missing Data Report



Table 46 Paediatric assessment at entry - mainstream school

Variable	2019	2020	2021	2022	2023
Frequency	10	18	18	23	11
Attendance limited by dialysis? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Attendance limited by renal health? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Supervised education support? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Additional education support? (If in mainstream school)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)

Table 47 Paediatric assessment at survey

Variable	2019	2020	2021	2022	2023
Frequency	357	355	358	365	362
Height	17 (4.8%)	32 (9.0%)	8 (2.2%)	6 (1.6%)	34 (9.4%)
Weight	13 (3.6%)	31 (8.7%)	4 (1.1%)	2 (0.5%)	32 (8.8%)
Paediatric Assessment at end of each Survey	14 (3.9%)	26 (7.3%)	3 (0.8%)	2 (0.5%)	31 (8.6%)

Table 48 Paediatric assessment at survey - mainstream school

Variable	2019	2020	2021	2022	2023
Frequency	257	245	267	263	236
Attendance limited by dialysis? (If in mainstream school)	1 (0.4%)	2 (0.8%)	2 (0.7%)	0 (0.0%)	0 (0.0%)
Attendance limited by renal health? (If in mainstream school)	1 (0.4%)	2 (0.8%)	2 (0.7%)	1 (0.4%)	0 (0.0%)
Supervised education support? (If in mainstream school)	1 (0.4%)	2 (0.8%)	2 (0.7%)	1 (0.4%)	0 (0.0%)
Additional education support? (If in mainstream school)	1 (0.4%)	2 (0.8%)	2 (0.7%)	1 (0.4%)	0 (0.0%)

Table 49 Parenthood data

Variable	2019	2020	2021	2022	2023
Frequency	45	58	61	45	25
Pregnancy outcome	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Neonatal survival	6 (13.3%)	11 (19.0%)	6 (9.8%)	1 (2.2%)	3 (12.0%)
Gestational age (best clinical estimate, weeks)	8 (17.8%)	5 (8.6%)	4 (6.6%)	5 (11.1%)	0 (0.0%)
Diabetes	21 (46.7%)	38 (65.5%)	30 (49.2%)	23 (51.1%)	13 (52.0%)
Hypertension (Somanz 2014 definition)	24 (53.3%)	35 (60.3%)	29 (47.5%)	23 (51.1%)	13 (52.0%)
CYA Immunosuppression at conception	9 (20.0%)	11 (19.0%)	14 (23.0%)	6 (13.3%)	10 (40.0%)
AZA Immunosuppression at conception	8 (17.8%)	10 (17.2%)	13 (21.3%)	6 (13.3%)	9 (36.0%)
Pred Immunosuppression at conception	8 (17.8%)	9 (15.5%)	13 (21.3%)	6 (13.3%)	9 (36.0%)
Tac Immunosuppression at conception	8 (17.8%)	9 (15.5%)	13 (21.3%)	6 (13.3%)	9 (36.0%)
MMF Immunosuppression at conception	9 (20.0%)	10 (17.2%)	14 (23.0%)	6 (13.3%)	10 (40.0%)
Sirol Immunosuppression at conception	10 (22.2%)	11 (19.0%)	14 (23.0%)	6 (13.3%)	10 (40.0%)
Other Immunosuppression at conception	10 (22.2%)	12 (20.7%)	15 (24.6%)	6 (13.3%)	10 (40.0%)
Labour type	25 (55.6%)	34 (58.6%)	32 (52.5%)	23 (51.1%)	13 (52.0%)
Delivery type	24 (53.3%)	34 (58.6%)	32 (52.5%)	23 (51.1%)	13 (52.0%)
Congenital condition present?	6 (13.3%)	7 (12.1%)	6 (9.8%)	1 (2.2%)	2 (8.0%)

ANZDATA Missing Data Report



Table 50 Parenthood birthweight data

Variable	2019	2020	2021	2022	2023
Frequency	42	52	56	45	22
Weight at birth (gms)	8 (19.0%)	8 (15.4%)	5 (8.9%)	5 (11.1%)	2 (9.1%)

Table 51 Parenthood creatinine prior to conception

Variable	2019	2020	2021	2022	2023
Frequency	13	20	24	20	8
Creatinine prior to conception (umol/L)	1 (7.7%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (12.5%)

Table 52 Parenthood creatinine post delivery

Variable	2019	2020	2021	2022	2023
Frequency	13	20	23	20	6
Creatinine 3 months post delivery (umol/L)	3 (23.1%)	6 (30.0%)	3 (13.0%)	1 (5.0%)	2 (33.3%)

Table 53 Non-skin cancer data

Variable	2019	2020	2021	2022	2023
Frequency	801	783	724	681	674
Cancer type	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Primary site of cancer category	22 (2.7%)	19 (2.4%)	14 (1.9%)	10 (1.5%)	1 (0.1%)
Cancer staging code	81 (10.1%)	57 (7.3%)	38 (5.2%)	20 (2.9%)	13 (1.9%)
Type 1st treatment	77 (9.6%)	74 (9.5%)	52 (7.2%)	38 (5.6%)	15 (2.2%)